In the phase 3 SKYLIGHT 1 randomized controlled trial, the non-hormonal neuro…
In the phase 3 SKYLIGHT 1 randomized controlled trial, the non-hormonal neurokinin-3 receptor antagonist fezolinetant produced statistically significant reductions in the frequency and severity of moderate-to-severe hot flashes versus placebo at weeks 4 and 12, with improvement s
Advisory — derived radar signal (confidence + source fields), not an authoritative classification.
- Type
- evidence-claim
- Domain
- menopause
- Grade
- B
- License
- proprietary-research-use
- instance
- m322
- domain_slug
- menopause
- pubmed_ids
- 36924778
- evidence_grade
- B
- tags
- hot-flashes,non-hormonal,fezolinetant,what-works,newer-treatment,R1-verified-20260601
- source_ids
- PMID-36924778
Read-only aggregated view. Health Evidence is the source of record; this catalog shows provenance as-is — no ratings, no reviews.